Published in Vaccine Weekly, January 18th, 2006
According to recent research published in the Journal of Cancer Research and Clinical Oncology, "The purpose of this study was to investigate in vivo antitumor activity of newly synthesized N-sulfonylpyrimidine derivatives 1-(p-toluenesulfonyl)cytosine (4H), 1-(p-toluenesulfonyl)cytosine hydrochloride (4HxHCl) and zinc(II) complex of 1-(p-toluenesulfonyl)cytosine (4K). In order to do that we have used mouse anaplastic mammary carcinoma (AMCa). Tumor cells (106) in a volume of .02 ml were transplanted into the thigh of the right hind leg of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2006-01-18)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.